Dissecting the Dynamics of HIV-1 Protein Sequence Diversity

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Hu, Yongli ^a,c   Tan, Paul ThiamJoo ^b,d   Tan, Tin Wee ^c   August, J Thomas ^a,b   Khan, Asif M ^a,b  

^a PERDANA UNIVERSITY   (Malaysia)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d MINISTRY OF HEALTH   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; HLA ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; NEF PROTEIN; PROTEOME; T LYMPHOCYTE RECEPTOR; VIRUS ENVELOPE PROTEIN;

AMINO ACID COMPOSITION; ARTICLE; BINDING SITE; CLADISTICS; CONTROLLED STUDY; GENE MUTATION; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR DYNAMICS; PROTEIN MOTIF; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; DATABASES, GENETIC; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VARIATION; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PROTEOME; SEQUENCE ALIGNMENT; VIRAL PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84875955713     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059994     Document Type: Article

References (64)

1. Batschelet E, Domingo E, Weissmann C, (1976) The proportion of revertant and mutant phage in a growing population, as a function of mutation and growth rate. Gene 1: 27-32.
2. Eigen M, (1993) Viral quasispecies. Sci Am 269: 42-49.
3. Domingo E, Menendez-Arias L, Holland JJ, (1997) RNA virus fitness. Rev Med Virol 7: 87-96.
4. Biebricher CK, Eigen M, (2006) What is a quasispecies? Curr Top Microbiol Immunol 299: 1-31.
5. Lauring AS, Andino R, (2010) Quasispecies theory and the behavior of RNA viruses. PLoS Pathog 6: e1001005.
6. Wain-Hobson S, (1993) The fastest genome evolution ever described: HIV variation in situ. Curr Opin Genet Dev 3: 878-883.
7. Holland J, Spindler K, Horodyski F, Grabau E, Nichol S, et al. (1982) Rapid evolution of RNA genomes. Science 215: 1577-1585.
8. Jetzt AE, Yu H, Klarmann GJ, Ron Y, Preston BD, et al. (2000) High rate of recombination throughout the human immunodeficiency virus type 1 genome. J Virol 74: 1234-1240.
9. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF, (2010) The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 10: 11-23.
10. Boutwell CL, Rolland MM, Herbeck JT, Mullins JI, Allen TM, (2010) Viral evolution and escape during acute HIV-1 infection. J Infect Dis 202 (Suppl 2): S309-314.
11. Troyer RM, McNevin J, Liu Y, Zhang SC, Krizan RW, et al. (2009) Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog 5: e1000365.
12. Abram ME, Ferris AL, Shao W, Alvord WG, Hughes SH, (2010) Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication. J Virol 84: 9864-9878.
13. Liu Y, McNevin JP, Holte S, McElrath MJ, Mullins JI, (2011) Dynamics of viral evolution and CTL responses in HIV-1 infection. PLoS One 6: e15639.
14. Barouch DH, Korber B, (2010) HIV-1 vaccine development after STEP. Annu Rev Med 61: 153-167.
15. McBurney SP, Ross TM, (2008) Viral sequence diversity: challenges for AIDS vaccine designs. Expert Rev Vaccines 7: 1405-1417.
16. Walker BD, Burton DR, (2008) Toward an AIDS vaccine. Science 320: 760-764.
17. Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM, (2008) The challenge of HIV-1 subtype diversity. N Engl J Med 358: 1590-1602.
18. Rammensee HG, (1995) Chemistry of peptides associated with MHC class I and class II molecules. Curr Opin Immunol 7: 85-96.
19. Wucherpfennig KW, Call MJ, Deng L, Mariuzza R, (2009) Structural alterations in peptide-MHC recognition by self-reactive T cell receptors. Current opinion in immunology 21: 590-595.
20. Blankson JN, (2010) Control of HIV-1 replication in elite suppressors. Discovery medicine 9: 261-266.
21. Ndhlovu ZM, Proudfoot J, Cesa K, Alvino DM, McMullen A, et al. (2012) Elite controllers with low to absent effector CD8+ T cell responses maintain highly functional, broadly directed central memory responses. Journal of virology 86: 6959-6969.
22. Autran B, Descours B, Avettand-Fenoel V, Rouzioux C, (2011) Elite controllers as a model of functional cure. Current opinion in HIV and AIDS 6: 181-187.
23. Mudd PA, Martins MA, Ericsen AJ, Tully DC, Power KA, et al. (2012) Vaccine-induced CD8+ T cells control AIDS virus replication. Nature 491: 129-133.
24. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, et al. (2011) Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473: 523-527.
25. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, et al. (2009) Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nature medicine 15: 293-299.
26. Kawada M, Tsukamoto T, Yamamoto H, Iwamoto N, Kurihara K, et al. (2008) Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial. Journal of virology 82: 10199-10206.
27. Tsukamoto T, Takeda A, Yamamoto T, Yamamoto H, Kawada M, et al. (2009) Impact of cytotoxic-T-lymphocyte memory induction without virus-specific CD4+ T-Cell help on control of a simian immunodeficiency virus challenge in rhesus macaques. Journal of virology 83: 9339-9346.
28. Wheeler DL, Barrett T, Benson DA, Bryant SH, Canese K, et al. (2005) Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 33: D39-45.
29. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ, (1990) Basic local alignment search tool. J Mol Biol 215: 403-410.
30. Koo QY, Khan AM, Jung KO, Ramdas S, Miotto O, et al. (2009) Conservation and variability of West Nile virus proteins. PLoS One 4: e5352.
31. Khan AM, Miotto O, Nascimento EJ, Srinivasan KN, Heiny AT, et al. (2008) Conservation and variability of dengue virus proteins: implications for vaccine design. PLoS Negl Trop Dis 2: e272.
32. Heiny AT, Miotto O, Srinivasan KN, Khan AM, Zhang GL, et al. (2007) Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets. PLoS One 2: e1190.
33. Leitner T, Korber B, Daniels M, Calef C, Foley B (2005) HIV-1 Subtype and Circulating Recombinant Form (CRF) Reference Sequences, 2005. The Human Retroviruses and AIDS 2005 Compendium. Los Alamos: Los Alamos National Laboratory.
34. Yokoyama S, Gojobori T, (1987) Molecular evolution and phylogeny of the human AIDS viruses LAV, HTLV-III, and ARV. Journal of molecular evolution 24: 330-336.
35. Pei J, Kim BH, Grishin NV, (2008) PROMALS3D: a tool for multiple protein sequence and structure alignments. Nucleic Acids Res 36: 2295-2300.
36. Thompson JD, Higgins DG, Gibson TJ, (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22: 4673-4680.
37. Thompson JD, Thierry JC, Poch O, (2003) RASCAL: rapid scanning and correction of multiple sequence alignments. Bioinformatics 19: 1155-1161.
38. Ratner L, Haseltine W, Patarca R, Livak KJ, Starcich B, et al. (1985) Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313: 277-284.
39. Sahu GK, Sarria JC, Cloyd MW, (2010) Recovery of replication-competent residual HIV-1 from plasma of a patient receiving prolonged, suppressive highly active antiretroviral therapy. J Virol 84: 8348-8352.
40. Khan AM, Heiny AT, Lee KX, Srinivasan KN, Tan TW, et al. (2006) Large-scale analysis of antigenic diversity of T-cell epitopes in dengue virus. BMC Bioinformatics 7 (Suppl 5): S4.
41. Khan AM, Miotto O, Heiny AT, Salmon J, Srinivasan KN, et al. (2006) A systematic bioinformatics approach for selection of epitope-based vaccine targets. Cell Immunol 244: 141-147.
42. Brusic V, Zeleznikow J, (1999) Computational binding assays of antigenic peptides. Letters in Peptide Science 6: 313-324.
43. Shannon CE (1948) A mathematical theory of communication. Bell System Technical Journal 27: 379-423 and 623-656.
44. Miotto O, Heiny A, Tan TW, August JT, Brusic V, (2008) Identification of human-to-human transmissibility factors in PB2 proteins of influenza A by large-scale mutual information analysis. BMC Bioinformatics 9 (Suppl 1): S18.
45. Korber BT, Foley BT, Kuiken CL, Pillai SK, Sodroski JG (1998) Numbering Positions in HIV Relative to HXB2CG. Human Retroviruses and AIDS.
46. Eigen M, Schuster P, (1977) The hypercycle. A principle of natural self-organization. Part A: Emergence of the hypercycle. Die Naturwissenschaften 64: 541-565.
47. Klenerman P, Zinkernagel RM, (1998) Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature 394: 482-485.
48. Purbhoo MA, Sewell AK, Klenerman P, Goulder PJ, Hilyard KL, et al. (1998) Copresentation of natural HIV-1 agonist and antagonist ligands fails to induce the T cell receptor signaling cascade. Proc Natl Acad Sci U S A 95: 4527-4532.
49. Reid SW, McAdam S, Smith KJ, Klenerman P, O'Callaghan CA, et al. (1996) Antagonist HIV-1 Gag peptides induce structural changes in HLA B8. J Exp Med 184: 2279-2286.
50. Klenerman P, Meier UC, Phillips RE, McMichael AJ, (1995) The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virus. European journal of immunology 25: 1927-1931.
51. Sewell AK, Harcourt GC, Goulder PJ, Price DA, Phillips RE, (1997) Antagonism of cytotoxic T lymphocyte-mediated lysis by natural HIV-1 altered peptide ligands requires simultaneous presentation of agonist and antagonist peptides. Eur J Immunol 27: 2323-2329.
52. Kirksey TJ, Pogue-Caley RR, Frelinger JA, Collins EJ, (1999) The structural basis for the increased immunogenicity of two HIV-reverse transcriptase peptide variant/class I major histocompatibility complexes. J Biol Chem 274: 37259-37264.
53. Moschella F, Ombra MN, Del Pozzo G, Guardiola J, (2003) Administration of different antigenic forms of altered peptide ligands derived from HIV-1 RTase influences their effects on T helper cell activation. Hum Immunol 64: 1-8.
54. Streeck H, Brumme ZL, Anastario M, Cohen KW, Jolin JS, et al. (2008) Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med 5: e100.
55. Sauce D, Larsen M, Fastenackels S, Pauchard M, Ait-Mohand H, et al. (2011) HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood 117: 5142-5151.
56. Bouhdoud L, Villain P, Merzouki A, Arella M, Couture C, (2000) T-cell receptor-mediated anergy of a human immunodeficiency virus (HIV) gp120-specific CD4(+) cytotoxic T-cell clone, induced by a natural HIV type 1 variant peptide. J Virol 74: 2121-2130.
57. Almeida RR, Rosa DS, Ribeiro SP, Santana VC, Kallas EG, et al. (2012) Broad and cross-clade CD4+ T-cell responses elicited by a DNA vaccine encoding highly conserved and promiscuous HIV-1 M-group consensus peptides. PLoS One 7: e45267.
58. Kothe DL, Li Y, Decker JM, Bibollet-Ruche F, Zammit KP, et al. (2006) Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology. 352: 438-449.
59. Nickle DC, Rolland M, Jensen MA, Pond SL, Deng W, et al. (2007) Coping with viral diversity in HIV vaccine design. PLoS Comput Biol 3: e75.
60. Thomson SA, Jaramillo AB, Shoobridge M, Dunstan KJ, Everett B, et al. (2005) Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use. Vaccine 23: 4647-4657.
61. Malm M, Rollman E, Ustav M, Hinkula J, Krohn K, et al. (2005) Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH. Viral immunology 18: 678-688.
62. Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, et al. (2007) Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 13: 100-106.
63. Barouch DH, O'Brien KL, Simmons NL, King SL, Abbink P, et al. (2010) Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 16: 319-323.
64. Stephenson KE, SanMiguel A, Simmons NL, Smith K, Lewis MG, et al. (2012) Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys. Journal of virology 86: 11434-11440.